UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free ...

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding olanzapine (Zyprexa) to a standard antiemetic regimen displayed safety and efficacy in preventing radiation-induced nausea and vomiting (RINV) for patients receiving abdominal/pelvic ...